Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR3 | P49682 | 9/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | PRKAA2 | P54646 | 3/20 | 0.47 |
| ▸ | MCHR1 | Q99705 | 2/20 | 0.46 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.46 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.44 |
| ▸ | HTR2A | P28223 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5577738 | 0.96 | OPRM1 (0.52) | CXCR3MAPTPRKAA2MCHR1OPRM1 | |
| SCHEMBL5577679 | 0.86 | GAA (0.49) | CXCR3MAPTMCHR1GAA | |
| SCHEMBL5577303 | 0.85 | CCR1 (0.50) | CXCR3PRKAA2MCHR1CHRM1HTR2A | |
| SCHEMBL5577304 | 0.85 | CXCR3 (0.46) | CXCR3 | |
| SCHEMBL5577596 | 0.83 | MCHR1 (0.47) | CXCR3MAPTMCHR1GAA | |
| SCHEMBL5577341 | 0.83 | CHRM4 (0.47) | CXCR3MCHR1CYP2D6CHRM1HTR2A | |
| SCHEMBL5577831 | 0.83 | DRD2 (0.45) | PRKAA2MCHR1OPRM1CYP2D6CHRM1 | |
| SCHEMBL5577558 | 0.82 | MT-CO2 (0.47) | CXCR3PRKAA2 | |
| SCHEMBL5577645 | 0.82 | SCN10A (0.54) | CXCR3MAPTPRKAA2MCHR1 | |
| SCHEMBL5577358 | 0.80 | DRD2 (0.46) | CXCR3MCHR1HTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070043079-A1 | Heterocyclic compound containing nitrogen atom and use thereof | ONO PHARMACEUTICAL CO., LTD. (JP) | 2007-02-22 | — | — | US | disclosed |
| EP-1616862-A1 | NITROGENOUS HETEROCYCLIC COMPOUND AND USE THEREOF | ONO PHARMACEUTICAL CO., LTD. (JP) | 2006-01-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070043079-A1 | Heterocyclic compound containing nitrogen atom and use thereof | HLA-DRB1, MIF, HLA-C | CXCR3 32/4885MAPT 449/4885PRKAA2 4492/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.